Biosergen’s warrants of series TO2 are admitted to trading

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, CANADA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

The rights issue of shares and warrants in Biosergen AB (“Biosergen” or the “Company”) was registered at the Swedish Companies Registration Office on October 14, 2022. The warrants of series TO2 will be trading on Nasdaq First North Growth Market starting October 26, 2022, under the ticker “BIOSGN TO2” with ISIN-code SE0018588220.

The warrants
The warrants of series TO2 that was included in the rights issue of units in September 2022, have now been registered at the Swedish Companies Registration Office and the Company has received approval from Nasdaq for the warrants to be admitted to trading. First day of trading in the warrants of series TO2 has been set to October 26, 2022.

One (1) warrant of series TO2 entitles subscription of one (1) new share in the Company during the exercise period that runs from and including August 14 up to and including August 25, 2023. The subscription price for one (1) share will correspond to 70 percent of the volume weighted average price during the period from and including July 28 up to and including August 10, 2023. The subscription price can’t be lower than the quota value of the Company’s share or higher than SEK 4.5, meaning that the Company can raise a maximum of SEK 39 million through the warrants of series TO2.

Advisers
Mangold Fondkommission AB is the financial adviser to Biosergen in connection with the Rights Issue. Advokatfirman Lindahl KB is the legal adviser to the Company in connection with the Rights Issue.